A1494350
LFM-A13 , ≥97% , 244240-24-2
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB399.20 | In Stock |
|
| 10mg | RMB535.20 | In Stock |
|
| 25mg | RMB1119.20 | In Stock |
|
| 50mg | RMB2015.20 | In Stock |
|
| 100mg | RMB3631.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 150-151 °C |
| Boiling point: | 487.9±45.0 °C(Predicted) |
| Density | 1.909±0.06 g/cm3(Predicted) |
| storage temp. | −20°C |
| solubility | DMSO: 15 mg/mL |
| form | powder |
| pka | 5.20±0.50(Predicted) |
| color | white |
| Stability: | Stable for 2 years from date of purchase as supplied. PROTECT FROM MOISTURE. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| InChI | InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6- |
| InChIKey | UVSVTDVJQAJIFG-VURMDHGXSA-N |
| SMILES | C(NC1=CC(Br)=CC=C1Br)(=O)/C(/C#N)=C(\O)/C |
Description and Uses
LFM-A13 (244240-24-2) is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC50‘s = 2.5 μM (recombinant BTK) and 17.2 μM (human BTK).1,2 It has also been shown to inhibit Polo-like kinase (PLK) – IC50 = 61 μM for human PLK3.3 LFM-A13 displayed no activity (concentrations up to 278 μM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten other tyrosine kinases.3
LFM-A13 is a potent inhibitor of Polo-like kinase (PLK), used for anti-breast cancer activity. Also a specific Bruton’s tyrosine kinase inhibitor.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302+H312+H332 |
| Precautionary statements | P261-P264-P280-P301+P312-P302+P352+P312-P304+P340+P312 |
| Hazard Codes | Xn |
| Risk Statements | 20/21/22 |
| Safety Statements | 36/37 |
| WGK Germany | 3 |
